AdjuCor enters BMBF supported research collaboration for developing 3D printable biomimetic polymers that mimic properties of the pericardium.
MUNICH, Germany – February 4th, 2020: In the future, novel polymers should make it possible to individually manufacture artificial elastic tissue replacements for pericardium, heart valves or blood vessels. In the PolyKARD project, biomimetic polymers are being developed that can imitate the mechanical properties of pericardial tissue. Using 3D printing and electrospinning, these polymers will be used to produce tailor-made implants. In addition, a 3D printer that can produce class III medical products is to be developed for the first time. The PolyKARD partners - AdjuCor GmbH, the Fraunhofer Institute for Applied Polymer Research IAP, the NMI Natural and Medical Sciences Institute, Young Optics Europe GmbH and pro3dure medical GmbH - plan to advance the production of the implants until the first clinical studies, probably in 2022.
Heart disease is one of the most frequent cause of death. Approximately 23 million people worldwide suffer from cardiac insufficiency ̶ and the number is increasing. In contrast, the number of heart transplants is stagnating at about 3000 transplants per year worldwide. Artificially produced implants could help many patients who are waiting for a donor organ. The 3D printing of precisely fitting implants has become indispensable in medicine, for example in orthopedics or dental surgery. However, there is a much greater need for research into implants that are intended to replace elastic tissue, because the demands on the materials are high: they must retain their mechanical properties for many years, be 100 percent resistant and biocompatible, and must not cause rejection reactions by the immune system. The latter is particularly important for materials that are permanently in contact with the body.
New polymers for modern printing technologies and individual medical technology
In the PolyKARD project, biomimetic polymers are being developed to mimic the biological and mechanical material properties of the pericardium. The pericardium is a collagen-containing and mechanically extremely stable structure that surrounds the heart. Clinically, the pericardium of cattle or pigs is already used to replace human heart valves or to reconstruct blood vessels. However, the processing of animal tissue is expensive and does not guarantee long-term mechanical stability. Other problems include the unreliable quality due to the great variability between donor animals as well as ethical and religious aspects.
'In this project, we are developing biomimetic pericardial replacement materials that can be used, for example, for artificial pericardium, heart valves, blood vessels, stents, tendons or septum occlusions. The special feature of these implants is that they are made of photopolymers and can be produced individually using a 3D printer or electrospinning. The monomers are developed as inks or resins. They only polymerize when they are irradiated with UV light', explains Dr. Wolfdietrich Meyer, who heads the project at the Fraunhofer IAP in Potsdam. The research team at the Fraunhofer IAP is synthesizing a photocrosslinkable material consisting of different polyurethane segments and collagen components.
Elastic, biocompatible and resistant
The newly synthesized polymers are tested for in vitro cytotoxicity at the NMI in Reutlingen according to DIN EN ISO 10993-5. The polymers are processed using different 3D printing methods and electrospinning. At the NMI, this spinning process is used to create porous structures that can grow together with the patient's own body tissue. The carrier substrates produced are characterized in terms of their mechanical and biological properties. Special emphasis is placed on the reproduction of the mechanical properties of the pericardium and the growth behavior of cells.
The first application of the biomimetic polymer will be the printing of a novel surface for an extravascular cardiac support system. The system of the Munich-based AdjuCor GmbH is based on a patient-specific mechanical implant, which is positioned completely outside the blood flow (extravascular) in the pericardial cavity around the epicardial surface of both heart chambers. 'A biomimetic pericardial replacement material would cause only minor immune reactions and would thus lead to a gentle healing phase. This could further shorten intensive care and hospital stays', explains heart surgeon and CEO of AdjuCor Prof. Stephen Wildhirt.
On the way to marketability
In order to be approved for clinical applications on the market in the future, both the new photopolymers and the processing methods must meet extensive requirements. For the largescale production of photopolymers, the GMP (Good Manufacturing Practice) guidelines must be observed. They ensure the quality of the production processes and environment. The company pro3dure medical GmbH Iserlohn will establish the upscaling process of the photopolymers as well as the resin synthesis under consideration of these GMP.
Young Optics Europe GmbH in Jena processes previously biocompatible photopolymers for products of medical classes I - IIa with the 3D printers they have developed. Within the PolyKARD project, a 3D printing system for the production of class III medical products is to be established for the first time, which will also enable complete traceability of the raw materials used for production.
Using holistic chemistry to create new materials
The three-year PolyKARD project started in April 2019 and is being implemented by the VDI Verein Deutscher Ingenieure e.V. as project management agency, on behalf of the BMBF under the funding measure 'Material Innovations for Healthy Living: ProMatLeben - Polymers' (FKZ: 13XP5087D). The partners will meet again on 4 February 2020 to present first milestones. ' We have already successfully synthesized and printed the first elastic photourethane resins from non-toxic starting materials', explains Wolfdietrich Meyer.
'In the future, we would like to apply the medical concept of wholeness even more strongly to our chemistry. We want to develop more materials based on renewable raw materials for 3D printing and electrospinning that are biocompatible and can be processed with the highest precision. We are also keeping an eye on the life cycle of the component and, if necessary, environmentally friendly disposal,' says Meyer.
AdjuCor’s Innovative Extravascular, Biventricular Cardiac Support Technology
What sets AdjuCor’ patented technology apart from the other LVADs currently available on the market, is its unique non-blood-contacting solution, its ability to support both ventricles, and its innovative patient-specific design. It is implanted by a heart team (cardiologist and cardiac surgeon) around the heart within a few minutes on the beating heart without sutures. It completely avoids blood contact and thereby any blood-related complications including strokes and bleeding – an invaluable advantage that cannot be over-stated. The energy transferred to the heart may be adjusted to each patient’s need. It thereby dramatically enhances the care of patients with heart failure and improves their quality of life.
AdjuCor was founded as GmbH in 2012 by the Cardiothoracic Surgeon Stephen Wildhirt and is funded by private investors, the European Union, as well as German and Bavarian entities. The company employs over thirty experts in all fields required and has received over 13 million euros of financing.
Contact: pr@adjucor.com
Read article on: Fraunhofer IAP
-
Most popular related searches
Related products
AdjuCor - Heart Failure Treating Technology
Related news
-
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world. Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such...
-
Diaphragm Pacemaker for Teen Featured on WSB-TV Atlanta
Fourteen year-old Sedarius was recently featured on WSB-TV Atlanta as the first pediatric patient to receive surgery to implant a diaphragm pacemaker in the state of Georgia. Sedarius was diagnosed with CCHS when he was eight years old, and required a tracheotomy and ventilator to breathe while he slept. The Avery Breathing Pacemaker will allow him to breathe without the need for a trach or ventilator and help improve his quality of life. He was able to return home within a few days, and it is expected that he...
-
Christie Medical Holdings, Inc. Partners with DO-PA A.S. for Turkey Distribution
As the leader in vein visualization technology throughout the world, Christie’s high-quality, made-in-the USA, VeinViewer®Vision2 and VeinViewer® Flex, continue to provide customers with improved clinical outcomes such as increasing 1st stick success, decreasing medically not required PICC lines and enhancing patient satisfaction. We are committed to the continued growth of VeinViewer® as a standard of care and are excited to partner with DO-PA Inc. as our authorized distributor for Turkey.DO-PA...
-
Outlook on the Medical Ceramics Global Market to 2026 - Identify Key Drivers and Challenges
According to Fast. MR research the report titled Global Medical Ceramics Market provides comprehensive information regarding influential factors. Data included in the report has been curated by our team of industry experts, considering relevant information about the market. This report discusses the growth and trends of various regions and segments of the market. Information such as market drivers, restraints, opportunities, trends, gross revenue, average product/service price, and market share of major players...
-
BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson`s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in a Phase 1 (Ph1), open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease (PD). The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of DA01 in patients with PD. “It’s both exciting and humbling to be a part of...
Customer comments
No comments were found for AdjuCor enters BMBF supported research collaboration for developing 3D printable biomimetic polymers that mimic properties of the pericardium.. Be the first to comment!